Skip to Main content Skip to Navigation
New interface
Journal articles

The 5,6-epoxycholesterol metabolic pathway in cancer: emergence of new pharmacological targets

Abstract : Metabolic pathways have emerged as cornerstones in carcinogenic deregulation providing new therapeutic strategies for cancer management. This is illustrated by the recent discovery of a cholesterol metabolic branch involving the biochemical transformation of 5,6-epoxycholesterol (5,6-ECs). 5,6-ECs have been shown to be differentially metabolized in breast cancers (BC) compared to normal breast tissue. 5,6-ECs are metabolized into the tumour promoter oncosterone in BC, while they are transformed into the tumour suppressor metabolite dendrogenin A (DDA) in normal breast tissue. Blocking oncosterone’s mitogenic and invasive potential will represent new opportunities for BC treatment. The reactivation of DDA biosynthesis, or its use as a drug, represents promising therapeutic approaches such as DDA-deficiency complementation, activation of BC cell re-differentiation and BC chemoprevention. This review presents current knowledge as to the 5,6-EC metabolic pathway in BC focusing on the 5,6-EC metabolic enzymes ChEH and HSD11B2, and on 5,6-EC metabolite targets LXRβ and GR.
Document type :
Journal articles
Complete list of metadata
Contributor : Marc Poirot Connect in order to contact the contributor
Submitted on : Wednesday, December 23, 2020 - 10:49:06 AM
Last modification on : Wednesday, November 23, 2022 - 12:02:08 PM

Links full text




Philippe de Médina, Khadijetou Diallo, Emilie Huc Claustre, Mehdi Attia, Régis Soulès, et al.. The 5,6-epoxycholesterol metabolic pathway in cancer: emergence of new pharmacological targets. British Journal of Pharmacology, 2020, Online ahead of print. ⟨10.22541/au.159069407.75369904⟩. ⟨inserm-03086999⟩



Record views